An Observational Study of Circulating Tumor Cells and 18F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Nair, Viswam S ^a   Keu, Khun Visith ^a   Luttgen, Madelyn S ^b   Kolatkar, Anand ^b   Vasanawala, Minal ^c   Kuschner, Ware ^a,c   Bethel, Kelly ^d   Iagaru, Andrei H ^a   Hoh, Carl ^e   Shrager, Joseph B ^a,c   Loo, Billy W ^a   Bazhenova, Lyudmila ^f   Nieva, Jorge ^g   Gambhir, Sanjiv S ^a   Kuhn, Peter ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d SCRIPPS CLINIC   (United States)

^e UCSD MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g BILLINGS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL STRUCTURE; CIRCULATING TUMOR CELL; EARLY CANCER; FEMALE; GLUCOSE METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHLEBOTOMY; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME;

EID: 84879834620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067733     Document Type: Article

References (37)

1. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, et al. (2009) Circulating tumor cell as a diagnostic marker in primary lung cancer. Clinical Cancer Res 15: 6980-6986.
2. James ML, Gambhir SS, (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92: 897-965.
3. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK, (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285: 914-924.
4. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, et al. (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359: 1388-1393.
5. Warburg O, (1956) On respiratory impairment in cancer cells. Science 124: 269-270.
6. Jadvar H, Alavi A, Gambhir SS, (2009) 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50: 1820-1827.
7. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, et al. (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5: 612-619.
8. Dang CV, (2010) Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer research 70: 859-862.
9. Palaskas NJ, Larson SM, Schultz N, Komisopoulou E, Wong J, et al. (2011) 18F-fluorodeoxy-glucose positron emission tomography (18FDG-PET) marks MYC-overexpressing human basal-like breast cancers. Cancer research 5164-5174: 1-11.
10. Hou JM, Krebs M, Ward T, Sloane R, Priest L, et al. (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178: 989-996.
11. Paterlini-Brechot P, Benali NL, (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253: 180-204.
12. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
13. Scheel C, Weinberg RA, (2012) Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 22: 396-403.
14. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
15. Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, et al. (2008) Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 3: 971-978.
16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714.
17. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, et al. (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9: 016003.
18. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, et al. (2012) Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 9: 016005.
19. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, et al. (2012) High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol 9: 016004.
20. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, et al. (2004) A rare-cell detector for cancer. Proc Natl Acad Sci U S A 101: 10501-10504.
21. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, et al. (2012) Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 9: 016001.
22. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, et al. (2007) Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 13: 3255-3263.
23. Gulec SA, Suthar RR, Barot TC, Pennington K, (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38: 1289-1295.
24. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, et al. (2012) Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 13: 52-58.
25. Coleman RE, (1999) PET in lung cancer. J Nucl Med 40: 814-820.
26. Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, et al. (2009) Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 50: 1646-1654.
27. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C, (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2: 351-365.
28. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29: 1556-1563.
29. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, et al. (2011) Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 17: 827-835.
30. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, et al. (2010) 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51: 1213-1218.
31. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, et al. (2009) Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27: 3303-3311.
32. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, et al. (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391-2401.
33. Tanaka F YK, Hasegawa S, (2010) Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives. Lung Cancer: Targets and Therapy 1: 77-84.
34. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, et al. (2005) Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer research 65: 2378-2386.
35. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, et al. (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153: 865-873.
36. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, et al. (2003) Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer research 63: 3805-3811.
37. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584.